Future of Sales and Marketing beyond COVID - hybrid event in Vilnius: physical audience of 800 + 300 virtual. Digital marketing, location marketing. How to create MAGIC in new marketing campaigns. Future of Marketing Keynote Speaker

Chances of 2 people in 70 having same birthday? Managing Risk in Banking and Financial Services. Why the greatest risks are combinations of very unlikely events, which happen far more often than you expect. Keynote speaker on risk management

Compliance is Dead. How to build trust. Reputation of banks and financial services. Compliance Risks. Why 100% compliance with regulations, ESG requirements etc is often not enough to prevent reputational damage

Life's too short to do things you don't believe in! Why passionate belief in the true value of what you are selling or doing is the number one key to success. Secret of all leadership and marketing - keynote for 1100 people in Vilnius October 2021

Why you can't innovate on Zoom or Teams meetings - Innovation is almost impossible unless breathing same air, in same room

Why the key to rapid innovation is team diversity - survey global CEOs. Innovation keynote speaker

Future Manufacturing 5.0. Lessons from personal life for all manufacturers. Manufacturing Keynote

Future of Manufacturing: diagnostics; predictive analytics, little data and cybersecurity. Keynote

Manufacturing 5 0: The truth about robots, robotics and automation. Future of Manufacturing Keynote

Manufacturing 5.0 - why Manufacturing 4.0 not enough. Agility and Innovation: Manufacturing Keynote

Future of Manufacturing 5.0 - hyperconnected, sustainable factories and supply chains + human beings

80% of sales are won or lost in 3 seconds - Future of Marketing Keynote Speaker - Pardavimu formule

Celebrex - Vioxx - the battle continues

Futurist Keynote Speaker: Posts, Slides, Videos - Future Health Care and Pharma Keynote Speaker

Text of e-mail sent by Skip Weber: I understand that the gap between celebrex and vioxx is widening again. I have been told that scripts are now 56% to 44% and total market share over the last month is 64% to 36%. This is primarily due to two recent events:

1) The now combined sales forces of Searle, Pfizer, and Pharmacia & Upjohn have begun to push back against to the huge marketing campaign Merck has waged over the last 6 months.

2) Merck recently released a study that revealed a 5% increase in heart attacks for people taking vioxx. Merck has recommended that people taking vioxx also take at least two aspirin per day. Bad news for vioxx since naiads are what vioxx replaced. In another unrelated event, an appeals court has just stated that Merck should not have been issued a patent for vioxx since it infringed on the patent filed by Searle 7 months earlier. This will continue to be fought in the courts.

In 2000, celebrex has an advantage and that appears to be fairly steady. As far as total sales in 1999 and 2000, Celebrex just surpassed 2 billion. Vioxx has yet to hit one billion but will certainly hit a billion in the next month. While vioxx appears to be catching celebrex, and they may some day because they have a terrific sales force, the total dollar value of market share is widening. There is also a new arthritis drug hitting the market that may take as much a 5% of the market, according to my marketing friends.

There is also a patent infringement suit against Pharmacia that could hit Pharmacia Merck hard if it is upheld. I have been told that there is two reasons why Pharmacia was sued but not Merck. If Rochester U. beats Pharmacia, they have beaten Merck. Battling Pharmacia will be a less expensive battle than going against Merck's big legal guns. Also, it has been said the Merck is one of the major benefactors of Rochester U."


Related news items:
Newer news items:
Older news items:


Thanks for promoting with Facebook LIKE or Tweet. Really interested to read your views. Post below.

Join the Debate! What are your own views?


?

 

Search for your future



Our cookie policy

We use cookies for statistical purposes. To comply with the e-Privacy Directive we need to ask your consent to place these cookies on your computer.

Your use of this site indicates acceptance of these terms. I accept